Vanessa Dávila Conn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vanessa Dávila Conn has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Santiago Ávila-Ríos
Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
2 shared publications Akio Murakami-Ogasawara
Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
1 shared publicationCIENI-CEC Consortium
Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
1 shared publication- Claudia García-Morales
Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
1 shared publication - Daniela Tapia Trejo
Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
1 shared publication Daniela Tapia-Trejo
Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
HIV Transmission Dynamics in Greater Mexico City are Shaped by Dense Spatial Mixing
Understanding HIV transmission in densely populated urban settings is essential to mitigate ongoing epidemic spread. We present a comprehensive analysis of recent HIV transmission dynamics in Greater Mexico City, one of the world’s largest metropolitan areas comprising Mexico City and neighbouring municipalities of the State of Mexico. Drawing from over 7,000 complete pol gene sequences representing around 50% of new cases reported between 2019 and 2022 within the study region, we reconstructed the transmission network based on pairwise genetic distance. We identified ten large transmission clusters exhibiting sustained growth up to the most recent sampling period. We further analysed paired genetic and high-resolution human mobility data using an integrated phylogeographic approach. We observed a heterogeneous pattern of viral spread across the region, supported by an extensive mixing at a wider geographic scale. Across Greater Mexico City, displaying a high population density, HIV transmission is minimally spatially constrained, a pattern likely fuelled by intense human mobility. Thus, population movement weakens isolation by distance in large urban areas even for a chronic infection that is sexually and vertically transmitted. We demonstrate the value of integrating large-scale genetic, epidemiological, and mobility data to resolve contemporary HIV transmission dynamics in densely populated urban settings.
Open AccessHIV Transmission Dynamics in Greater Mexico City are Shaped by Dense Spatial Mixing
Understanding HIV transmission in densely populated urban settings is essential to mitigate ongoing epidemic spread. We present a comprehensive analysis of recent HIV transmission dynamics in Greater Mexico City, one of the world’s largest metropolitan areas comprising Mexico City and neighbouring municipalities of the State of Mexico. Drawing from over 7,000 complete pol gene sequences representing around 50% of new cases reported between 2019 and 2022 within the study region, we reconstructed the transmission network based on pairwise genetic distance. We identified ten large transmission clusters exhibiting sustained growth up to the most recent sampling period. We further analysed paired genetic and high-resolution human mobility data using an integrated phylogeographic approach. We observed a heterogeneous pattern of viral spread across the region, supported by an extensive mixing at a wider geographic scale. Across Greater Mexico City, displaying a high population density, HIV transmission is minimally spatially constrained, a pattern likely fuelled by intense human mobility. Thus, population movement weakens isolation by distance in large urban areas even for a chronic infection that is sexually and vertically transmitted. We demonstrate the value of integrating large-scale genetic, epidemiological, and mobility data to resolve contemporary HIV transmission dynamics in densely populated urban settings.
- Open Access
- 15 December 2023
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-12
SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City
Objective: To assess SARS-CoV-2 antibody prevalence and titers in people living with HIV (PLWHIV) on antiretroviral treatment (ART) enrolled at a tertiary reference hospital in Mexico. Methods: Two plasma aliquots per person, used for HIV viral load follow-up between 01/2020 and 09/2021, were used to assess total anti-N and neutralizing SARS-CoV-2 antibodies. Sociodemographic, clinical, and SARS-CoV-2 exposure risk information were collected. The risk associated with SARS-CoV-2 exposure and associations with antibody titers were analyzed with logistic, Cox, and linear multivariable models. Results: 803 PLWHIV participated; 233 had detectable SARS-CoV-2 antibodies (prevalent cases), and 132 seroconverted (incident cases). Overall, the adjusted prevalence was 46.45%, with an incidence rate of 3.78 cases/100 person-months. Factors associated with prevalent cases included lower age, location (western zone of Mexico City and the neighboring Mexico State), use of public transport, attendance at meetings without social distancing, and higher CD4 + T cell counts (p < 0.05; multivariable logistic model). BNT162b2 vaccination reduced incident cases (Cox adjusted HR = 0.4; p = 0.013). Notably, previously infected and vaccinated individuals showed maximization of neutralizing activity (p < 0.001). No associations between SARS-CoV-2 neutralization and HIV-related variables (CD4 + T cell counts, viral load, number of years in viral suppression, ART regimen) were found in multivariable analysis. Conclusions: SARS-CoV-2 infection was associated with community risk rather than HIV-associated variables in PLWH on ART and clinical follow-up. Antibody neutralization activity in vaccinated participants was maximized with previous SARS-CoV-2 infection.
- 15 December 2023
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-12
Open AccessSARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City
Objective: To assess SARS-CoV-2 antibody prevalence and titers in people living with HIV (PLWHIV) on antiretroviral treatment (ART) enrolled at a tertiary reference hospital in Mexico. Methods: Two plasma aliquots per person, used for HIV viral load follow-up between 01/2020 and 09/2021, were used to assess total anti-N and neutralizing SARS-CoV-2 antibodies. Sociodemographic, clinical, and SARS-CoV-2 exposure risk information were collected. The risk associated with SARS-CoV-2 exposure and associations with antibody titers were analyzed with logistic, Cox, and linear multivariable models. Results: 803 PLWHIV participated; 233 had detectable SARS-CoV-2 antibodies (prevalent cases), and 132 seroconverted (incident cases). Overall, the adjusted prevalence was 46.45%, with an incidence rate of 3.78 cases/100 person-months. Factors associated with prevalent cases included lower age, location (western zone of Mexico City and the neighboring Mexico State), use of public transport, attendance at meetings without social distancing, and higher CD4 + T cell counts (p < 0.05; multivariable logistic model). BNT162b2 vaccination reduced incident cases (Cox adjusted HR = 0.4; p = 0.013). Notably, previously infected and vaccinated individuals showed maximization of neutralizing activity (p < 0.001). No associations between SARS-CoV-2 neutralization and HIV-related variables (CD4 + T cell counts, viral load, number of years in viral suppression, ART regimen) were found in multivariable analysis. Conclusions: SARS-CoV-2 infection was associated with community risk rather than HIV-associated variables in PLWH on ART and clinical follow-up. Antibody neutralization activity in vaccinated participants was maximized with previous SARS-CoV-2 infection.